All Psiconáutica articles arranged alphabetically. A directory to navigate the complete archive since 1996.
#
- “Albert Hofmann: Chance, Fate, and the Origin of LSD”
- “Alexander Shulgin: The Chemist Who Mapped the Mind”
- “Cannabis and Chemotherapy Nausea: Evidence, Risks, and Alternatives”
- “Cannabis and PTSD: Between Self-Medication and Clinical Evidence”
- “Cannabis: Avoiding Distress or Learning to Face It?”
- “Cocaine: Pharmacology, Risks, and Myths of a Stimulant”
- “DMT: The Tryptamine Within Us”
- “Entheogen or Hallucinogen: Bouso and the Shaman Myth”
- “Hemp as Biomass: Future Energy or Old Green Myth?”
- “Heroin in Spanish Music: Between Warning, Mockery, and Transgression”
- “Hofmann at 100: His Farewell and the Chemistry of Psilocybin”
- “Ibogaine and Addiction: Promises, Clinical Evidence, and Limitations”
- “Mystery Cults of Rome: Attis, Isis, and Mithras”
- “Oral vs. Inhaled Cannabis: Key Insights for Cancer Patients”
- “Peter Tosh: A Guitar as a Rifle Against Babylon”
- “Psychedelics and Personal Transformation: Between the Threshold and the Community”
- “Selegiline: History and Promises of the MAO-B Inhibitor”
- “The Celtic Pharmacopeia: Mushrooms, Nightshades, and Hemp”
- “The Restless Child Business: ADHD, Labels, and Pills”
- “Where Cannabis Comes From: The Equatorial African Trail”
- ‘How LSD Originated: Hofmann and the Years Before the Discovery’
- ‘LSD: My Problem Child – Albert Hofmann’s Preface’
- ‘Opium as a “Smart Drug”: History and Critical Analysis’
- ‘Peyote, San Pedro, and Mescaline: Mind-Altering Cacti’
- 1D-LSD Synthesized for the First Time, Revealing Market Confusion
- 2026 European Drug Report: Harm Reduction Progress and Gaps
- 2C-B Falls Somewhere Between MDMA and Psilocybin
- 5-MeO-DMT and therapy: ten accounts of drinking behavior
- 5-MeO-DMT and Treatment-Resistant Depression: Early Trial Results
A
- A decade of drug checking in Spain: 71.5% of samples contain no adulterants
- A genetically modified plant produces DMT, psilocybin, and 5-MeO-DMT all at once
- A Single Dose of Psilocybin Leaves a Brain Signature After One Month
- Absinthe: Between the Green Fairy Myth and Chemical Reality
- Addiction, Spirituality, and Western Science
- Adolescent 25C-NBOMe Exposure Remodels Adult Social Behavior in Rats
- Adrenochrome: Anatomy of a Hoax Between QAnon and the Pandemic
- Adrenochrome: From Conspiracy Myth to Real Science
- Adrenochrome: Hidalgo’s Conclusion and Lingering Scientific Questions
- Adrenochrome: Osmond and Hoffer’s Self-Experiments
- Adrenochrome: The Psychedelic Myth vs. Real-World Experiences
- Adverse Effects of MDMA and Other Psychedelics: A US Survey
- Albert Hofmann and Ergot: The Origins of LSD
- Albert Hofmann Beyond LSD: Chemistry, Consciousness, and Mystery
- Alcohol Extractions
- Alert in Spain: Products Sold as CBD Contain Synthetics
- Alexander Shulgin: The Chemist Who Mapped the Mind
- Alzheimer’s Disease and Cannabidiol: Scientific Perspectives and Precautions
- Ann Shulgin’s “Secret Place” and the Enigma of 2C-D
- Anxiety, Interferon, and Cannabinoids: A Clinical Perspective
- Arizona Funds $5M Ibogaine Clinical Trial for TBI
- Aspirin or White Willow? The Truth About Common Painkillers
- Australia Relaxes Oversight for MDMA and Psilocybin Therapy
- Australia Relaxes Rules for Psilocybin and MDMA Therapy
- Ayahuasca Activates Brain’s Empathy Networks, Study Finds
- Ayahuasca and Depression: What the Randomized Placebo Trial Showed
B
- Bena-Riamba: The Sons of Hemp in 19th-Century Congo
- Berkeley Launches First Psilocybin Trial for Healthy Seniors
- Beyond THC and CBD: Minor Cannabinoids and Terpenes
- Beyond THC and CBD: The Therapeutic Potential of Minor Cannabinoids
- Beyond THC and CBD: The Vast World of Other Cannabinoids
- Biological Contaminants in Cannabis: Real Risks and Myths
- Bipartisan US Bill Aims to Reschedule Ibogaine from Schedule I
- Blinding Fails in Over 85% of MDMA and Placebo Trials
- Blue Lotus: Egyptian Myth, Alkaloids, and Psychoactive Legend
- Body Converts Legal LSD Analogs Into LSD, Study Finds
- Brain Study in Rats Reveals Mescaline’s Unique Effects
- Brazil’s Federal Prosecution Service Seeks Review of Ayahuasca Law
- Buprenorphine: History, Pharmacology, and Role in Addiction Treatment
- Burundanga: Between Media Myth and Toxicological Reality
C
- Canada Opens and Closes Supervised Consumption Sites Simultaneously
- Cannabidiol and Addictive Disorders: Evidence, Myths, and Cautions
- Cannabidiol for Myoclonus: Evidence, Risks, and Stress Management
- Cannabidiol: Between Therapeutic Hope and Scientific Reality
- Cannabis Addiction: Is It in the Plant or the Person?
- Cannabis Adulterants: What Forensic Lab Analyses Actually Reveal
- Cannabis Adulterants: What Laboratory Tests Reveal
- Cannabis and ADHD: Science, Legal Risks, and the Natural Myth
- Cannabis and Anorexia Nervosa: A Real Solution or a Risk?
- Cannabis and Chemotherapy: Symptom Management in Oncology
- Cannabis and Crohn’s Disease: Clinical Evidence and Risk Reduction
- Cannabis and Driving: Risks, Tolerance, and Legal Complexities
- Cannabis and Fertility: Between Medical Myth and Scientific Evidence
- Cannabis and Fibromyalgia: Medical Controversy and Symptom Relief
- Cannabis and HIV: Balancing Symptom Relief and Metabolic Health
- Cannabis and HIV: Scientific Evidence for Chronic Symptom Management
- Cannabis and Inflammatory Bowel Disease: Evidence, Risks, and Outlook
- Cannabis and Lung Health: Chronic Bronchitis and Risk Reduction
- Cannabis and Meditation: Examining the Content-Free Mind
- Cannabis and Memory: Between Scientific Myth and Clinical Reality
- Cannabis and Memory: The Culprit or a Factor in Chronic Pain?
- Cannabis and Migraine: Evidence, Myths, and Harm Reduction
- Cannabis and Multiple System Atrophy: A Critical Look
- Cannabis and Neurodegenerative Diseases: Alzheimer’s and Parkinson’s
- Cannabis and Neurodegenerative Diseases: MS, Alzheimer’s, and Parkinson’s
- Cannabis and Neuropathic Pain: Scientific Evidence for Management
- Cannabis and Parkinson’s Disease: Scientific Evidence and Risk Reduction
- Cannabis and Pregnancy: Scientific Evidence, Risks, and Patient Rights
- Cannabis and Rare Neurodegenerative Diseases: Evidence and Risk
- Cannabis and Rheumatoid Arthritis: Science and Risk Reduction
- Cannabis as an Adjuvant for Cauda Equina Syndrome: Evidence and Risks
- Cannabis Desserts: Traditional Infused Recipes
- Cannabis Vaporization: Scientific Advances and Harm Reduction
- Cannabis, Health, and Driving: Pain Relief vs. Roadside Testing
- Cannabis, Lung Cancer, and Science: Moving Beyond the Fear
- Cannabis, Type 2 Diabetes, and the Endocannabinoid System
- CBD and Pediatric Epilepsy: Between Clinical Hope and Scientific Caution
- Cebil and Yopo: The Seeds of Bufotenine
- Cheese and Dreams: Stilton Legends and the Science of Sleep
- CHEMSAFE Catalunya: Harm Reduction for Chemsex in Catalonia
- Chemsex: Between Clinical Reality and Media Narrative
- Cocaine Involved in One in Four Overdose Deaths in Europe
- Cocaine Purity and Adulteration: The Reality of the Illicit Market
- Cocaine Purity and Duration: Facts, Myths, and Harm Reduction
- Cognimiscence
- Colorado Creates Pilot Program to Research Ibogaine
- Colorado Launches State Ibogaine Research Pilot Program
- Colorado Opens the Door to Regulated Ibogaine Starting in August
- COMP360 Psilocybin Maintains Antidepressant Effect at 6 Months
- COMP360: pharmaceutical psilocybin clears pivotal phase 3 trial
- Company asks DEA to import DMT, 5-MeO-DMT, and MDMA for clinical trials
- Crack and Freebase Cocaine (Part II): Risks and Harm Reduction
- Cultivating Psilocybe cubensis: Biology, Culture, and Risks
- Cyanazenes Detected: Opioids That Bypass Nitazene Bans
- Cyanazenes: New Nitazenes Detectable by Test Strips
- Czechia legalizes medical psilocybin, but real-world access remains on hold
D
- Daily Psilocybin Microdosing Relieves Distress in Palliative Care
- Dalí: Exploring Alternate States Without Substances
- Danish Trial Combines Psilocybin and Apomorphine to Wake Coma Patients
- DEA Sets Threshold Distinguishing Kratom Leaf from 7-OH Extracts
- Delaware Regulates Harm Reduction and Decriminalizes Drug Paraphernalia
- Designer Benzodiazepines Found in Pills Sold as Anxiolytics
- DESOXY: The Shulgin Account of Emotional Blunting
- DESOXY: The Shulgin Account on Emotional Flattening
- Did Prehistoric European Populations Use Drugs? (Part I)
- Diné Nation Asks DEA to Exclude Mescaline from Manufacturing Permit
- DMT and Depression: Insights from Early Clinical Trials
- DMT from ayahuasca activates human neural stem cells in the lab
- DMT in Ayahuasca Protects Neurons in Parkinson’s Disease Model
- DMT stimulates human neural stem cell proliferation
- Drugs and Literature: Creation in Altered States
- Drugs and Mental Health: Between Scientific Evidence and Myths of Fear
- Dutch Coffee Shops: The Back Door Dilemma
E
- E-cigarettes and Cannabis: Controversies, Harm Reduction, and Science
- Ecstasy and Health: A Rigorous Analysis of Physical and Psychiatric Risks
- Ecstasy Cut with Heroin: Anatomy of an Urban Legend
- Eleusis and the Kykeon: Hofmann’s Ergot Hypothesis
- Eli Lilly buys 5-MeO-DMT nasal spray for up to $3.8 billion
- Eli Lilly buys AtaiBeckley’s 5-MeO-DMT for $3.8 billion
- Energy Control Detects PMMA in MDMA Pills Sold in Spain
- Ernst von Bibra, the Baron Who Cataloged the World’s Drugs
- Escohotado (I): The Philosopher, LSD, and Freak Ibiza
- Escohotado on Cannabis: Use, Abuse, and Prohibition
- Esketamine (Spravato): The Approved Antidepressant and How It Works
- Esketamine Alone in Treatment-Resistant Depression: What the 2025 Trial Shows
- Esketamine Replaces Opioids After Gynecological Surgery in New Trial
- Expiration of Psychoactive Substances: Chemical Stability and Storage
- Extended-Release Oral Ketamine: Less Dissociation in New Trial
F
- Fake hash laced with synthetic cannabinoids detected across Europe
- FDA calls public hearing on psychedelic therapy
- FDA Clears Human Trials for Ibogaine Derivative DMX-1001
- FDA Finalizes Psychedelic Guidance and Accelerates Psilocybin
- FDA Finally Sets Rules for Psychedelic Clinical Trials
- FDA Holds Public Hearing on the Future of Psychedelics
- FDA Opens Consultation on Plant and Fungi-Based Drugs
- FDA reports point to a strong cardiac signal for ibogaine
- FDA seeks public input on ibogaine clinical trial design
- FDA Warns 15 Online Stores Selling Ketamine Without Medical Oversight
- Fentanyl: Lethal Potency, Medical Paradox, and Harm Reduction
- Fifty Years of Decoding Cannabis: From Mechoulam to the Endocannabinoid System
- First Confirmed Case of ETH-LAD Intoxication Documented
- First Public NHS Trial Backs Psilocybin for Depression
- First Trial Tests Psilocybin for Bipolar II Depression
- First Trial Tests Psilocybin for Phantom Limb Pain
- France Tightens Monitoring of Long-Term Ketamine Use
- From Coffee to Ritalin: Stimulants, Childhood, and the ADHD Myth
- From the Canaries to Sonora: The Uncertain Route of Canary Broom
- Fuerteventura and Psychedelic Therapy: From Enthusiasm to Caution
G
- Gabon Bans All Exports of Iboga, the Plant Behind Ibogaine
- Gabon Declares Iboga a National Treasure and Creates Sovereign Fund
- Gecko Turner: Afromeño Soul, Remixes, and Creativity
- Getting High on Batteries: Anatomy of an Urban Legend
- Groove 3: Bassless Jazz and the Groove as Shared Trance
- Guerrilla Growing: Preparation and Land Selection
- Guide to Entheogenic and Psychoactive Plants
H
- Harm Reduction: Between Scientific Evidence and Political Rhetoric
- Hepatitis C and Cannabis: Balancing Liver Risk and Treatment
- Heroin and Music: A Historical and Pharmacological Analysis
- Heroin and Music: Between Rock Myth and Clinical Reality
- Heroin in the 21st Century: Stigma and Scientific Evidence
- Heroin-Assisted Treatment: Scientific Evidence and Harm Reduction
- Hofmann and Huxley: LSD Between Serendipity and Vision
- Hofmann and Psychotomimetics: A Map of Magic Drugs
- Hofmann, Huxley, and Jünger: Literature and Psychedelia
- How Anxiety Works: The Fear That Anticipates
- How Psilocybin Changes the Brain: Recent Evidence
I
- Iboga and Voacanga: The African Vision and the Myth of the Cure
- Ibogaine and Addiction: The Evidence Medicine Ignores
- Ibogaine and Opioids: What Science Knows About Dependency
- Ibogaine Cardiac Risks: QT Prolongation and Safety
- Ibogaine for Ketamine Addiction: First 17-Month Follow-Up Case
- Ibogaine for Traumatic Brain Injury: What Stanford Found
- Ibogaine Legality and Clinics Worldwide: What We Know
- Ibogaine: Washington coordinates six federal agencies to fast-track clinical research
- If Skiing Were Illegal: A Satire on Prohibitionism
- Inhaled 5-MeO-DMT Dose Reverses Postpartum Depression in Hours
- Inhaled DMT: Quality of Life Improvements Last Up to One Year
- Ireland Warns of Cathinones Sold as MDMA Before Festival
- Irish Parliamentary Committee Calls for Decriminalizing All Drugs
- Isaacs-Mertens Syndrome and Cannabis: Clinical Evidence and Harm Reduction
- Israel Authorizes Medical Psilocybin Manufacturing Under GMP Standards
- IV Ketamine vs. Esketamine: Large Study Reveals Differences
J
- Jenkem: The Myth of the Fecal Drug Debunked
- Johnson & Johnson Enters Non-Hallucinogenic Psychedelics with $85M
- Jurema: The Brazilian Plant Reviving the DMT Enigma
K
- Kanna (Sceletium tortuosum): The Mild Sedative of the San and Khoi
- Ketamine and Cancer Surgery: 176,000 Cases Show No Survival Benefit
- Ketamine and Esketamine Show Similar Efficacy in Real-World Settings
- Ketamine and MDMA Leave a Mark on DNA Methylation
- Ketamine and MDMA Leave Distinct Epigenetic Marks, Study Finds
- Ketamine and motivational therapy for smoking cessation tested in pilot study
- Ketamine and Psychotherapy for Chronic Neuropathic Pain
- Ketamine and Treatment-Resistant Depression: What the Clinical Evidence Shows
- Ketamine for Fibromyalgia: Sustained Relief for Two Years
- Ketamine in psychiatry: a review of 106 studies maps out the evidence
- Ketamine Raises Morning Cortisol and May Curb Suicidal Ideation
- Ketamine Relieves Pain Through Pathways Separate from Dissociation
- Ketamine Relieves Severe OCD, but Effects Fade Without Therapy
- Ketamine Relieves Treatment-Resistant Bipolar Depression in Trial
- Ketamine Repairs Brain Circuits in Treatment-Resistant Depression
- Ketamine Risks: Cystitis, Dependence, and the K-Hole
- Ketamine vs. Lidocaine for Refractory Cancer Pain
- Ketamine: Between Anesthesia and Neuronal Regeneration
- Key Takeaways From the FDA Public Hearing on Psychedelics
L
- Large Real-World Study Finds No Reduction in Suicide Attempts with Esketamine
- Large-Scale Trial Tests Ketamine for Post-Orthopedic Surgery Pain
- Largest Microdosing Meta-Analysis Finds No Difference From Placebo
- Largest Psychedelic Brain Mapping Reveals Common LSD Pattern
- Legal Biases in Drug Research: Between Fear and Science
- Legal psilocybin access in Germany hits a waiting list bottleneck
- Legal psilocybin: 2,363 cases and a safety signal to watch
- Long-Term Effects of Ritual Ayahuasca Use: Science and Harm Reduction
- Louisiana Uses Opioid Settlement Funds to Research Psychedelics
- Low-Dose Buprenorphine Extends Ketamine’s Anti-Suicide Effects
- Low-Dose Psilocybin: Identifying Thresholds in a Phase 1 Trial
- LSD Activates Adaptive Stress Programs in the Mouse Cortex
- LSD and Generalized Anxiety: What the Phase 2b Trial Revealed
- LSD and Music: Science, Perception, and Harm Reduction
- LSD and Suggestibility: Between Therapy, Risk, and the Mind
- LSD Applications in Psychotherapy: An Interrupted History
- LSD Deconstructed: Researchers Find Potential Antipsychotic Piece
- LSD Dose Improves Motor Learning the Next Day, Swiss Study Finds
- LSD Dose Outperforms Placebo for Anxiety in Phase 3 Trial
- LSD Microdosing Fails to Outperform Placebo for ADHD, Review Finds
- LSD Temporary Tattoos: Anatomy of an Urban Legend
- LSD Therapy: Why Research Actually Stalled
- LSD Without the Trip: BOL-148 Secures $8M for German Clinical Trials
- LSD, psilocybin, and 2C-B leave distinct traces in the brain
- LSD: Acute Effects, Pharmacological Profile, and Harm Reduction
- LSD: My Problem Child (Preface)
- Luxembourg Wastewater Reveals Weekend MDMA Use
M
- Major Real-World Study of Legal Psilocybin in Oregon Finds Benefits
- Mandrake, Lotus, and Lettuce: Psychoactives in Pharaonic Egypt
- Manslaughter Trial Begins for Death at Miami Beach Psychedelic Retreat
- Mapping Ayahuasca and DMT Trials: 26 Registries, Mostly Phase I
- Mapping the Ineffable: The Science of Measuring Subjective Effects
- Mapping the Invisible: Science and Subjectivity in Drug Effects
- Market Volatility: MDMA Purity and Adulteration in Spain
- MDMA and Pain Relief: Science, Risk, and Perspective
- MDMA and PTSD: What Phase 3 Trials Say About Efficacy
- MDMA and Social Bonding: Selective Empathy, Generosity, and Context
- MDMA Deaths in Australia Decline, But Rarely Occur in Isolation
- MDMA for PTSD Returns to FDA: Resilient Resubmits Application
- MDMA for PTSD: New FDA Submission Two Years Later
- MDMA reduces alcohol intake in rats bred to drink
- MDMA Trial Targets PTSD Stemming from Childhood Trauma
- MDMA, Empathy, and Compassion: Does It Transform Social Behavior?
- MDMA-Assisted Psychotherapy and Autism Spectrum Disorder
- Medicine, Poison, and Molecules: What Canary Broom Really Contains
- Mescaline Acts on the Cerebellum, Unlike LSD and Psilocybin
- Meta-Analysis of Seven Trials Shows MDMA Benefits for PTSD
- Meta-analysis reviews the efficacy of DMT for treating addiction
- Meta-analysis: Ketamine Reduces Relapse Only in the First Month
- Methadone for Opioid Addiction: History, Efficacy, and Harm Reduction
- Microdosing Does Not Improve Cognition, According to 2026 Review
- Modified DMT Extends Trip Duration to One Hour in Phase 1 Trial
- Modified Plant Produces DMT, 5-MeO-DMT, and Three Other Psychedelics
- More Ayahuasca Experience Linked to Better Mental Health
- Mouse Study Distinguishes DMT and 5-MeO-DMT Mechanisms
- Mouse Study Separates DMT’s Psychedelic Trip from Therapeutic Effects
- Multi-Drug Placebo Proposed to Improve Psilocybin Clinical Trials
- Multiple Sclerosis and Cannabinoids: An Evidence-Based Approach
- Multiple Sclerosis and Cannabinoids: Evidence-Based Symptom Relief
- Mystical Experiences Predict OCD Improvement with Psilocybin
N
- Naloxone and Opioid Overdose: Between Clinical Evidence and Social Barriers
- Naltrexone: Mechanisms, Risks, and Realities in Addiction Treatment
- Nausea During Pregnancy: Cannabis, Myths, and Safe Alternatives
- Navajo Community Asks DEA to Halt Industrial Mescaline Production
- Nearly 600 Psychedelic Users Validate a 1967 LSD Manual
- NEP: The Adulterant Now Dominating Mephedrone Sold in Spain
- Netherlands Issues Alert for Ecstasy Pills Containing PMMA
- Neural Map Details How Psilocybin Acts on the Brain
- New Mexico Opens Applications for Legal Psilocybin Program
- New South Wales Makes Festival Drug Checking Permanent
- New Zealand Authorizes Clinical MDMA for PTSD Treatment
- Nexus 2026: Consciousness, Art, and Cognitive Liberty
- NIDA Funds Ibogaine Opioid Addiction Trial in Boston
- Non-Psychedelic LSD Analog Slows Colorectal Cancer in Mice
- Non-Psychedelic MDMA Analog Shows Promise for PTSD
O
- On the Icaro, or Shamanic Chant
- One in Six Veterans With PTSD Could Be Barred From MDMA Therapy
- Opium and Coffee: The History of Smart Drugs in Europe
- Oral Ketamine Achieves Antidepressant Effect Without Dissociation
- Oral Psilocin Matches Psilocybin with Fewer Adverse Effects
- Oral vs. Inhaled Cannabis for Multiple Sclerosis: Balancing Safety
- Oregon drops proposed fee hike for legal psilocybin program
- Oregon Measures Legal Psilocybin: Reduced Depression and Anxiety
- Oregon Proposes Doubling Fees for Legal Psilocybin Program
- Orphines: The New Synthetic Opioids That Test Strips Can’t Detect
- Orthostatic Hypotension and Cannabis: Science, Prevention, and Safety
- Oxford finds clue to ketamine’s rapid action in the habenula
P
- Phantom Limb Pain and Cannabinoids: An Evidence-Based Approach
- Pharmaceutical LSD DT120 Improves Major Depression in Phase 3
- Pharmaceutical LSD DT120 Succeeds in Generalized Anxiety Trial
- Pilot Trial Treats Veteran PTSD With MDMA-Assisted Couples Therapy
- Plants That Promise a High and Deliver Nothing: Debunking Myths
- Porn Addiction: Superstimulus or Neurological Myth?
- Psilocybin and Alcoholism: What the JAMA Randomized Trial Shows
- Psilocybin and Alzheimer’s: A Case Study of Transient Improvements
- Psilocybin and Anorexia Nervosa: The First Feasibility Study
- Psilocybin and Cancer: Single Dose Shows Two-Year Benefits
- Psilocybin and Depression: Breaking the Rumination Loop
- Psilocybin and Depression: Neuroimaging, Regulation, and the Search for a New Therapy
- Psilocybin and Major Depression: What Recent Clinical Trials Say
- Psilocybin and Treatment-Resistant Depression: What the EPISODE Trial Shows
- Psilocybin for Anorexia Nervosa: Pilot Study Shows Sustained Gains
- Psilocybin for Bipolar II Depression: JAMA Psychiatry Trial Results
- Psilocybin for Migraine: 80% Response in Yale Pilot Trial
- Psilocybin for Persistent Lyme: A 20-Patient Pilot Study
- Psilocybin in Mice: Effects Persist Without Conscious Trip
- Psilocybin Protects Against Chemotherapy-Induced Nerve Damage
- Psilocybin Reduces Brain Damage from Repeated Hits in Rats
- Psilocybin Reduces Excessive Grooming in Rats via 5-HT2B Receptors
- Psilocybin Reorganizes the Brain Based on User Activity
- Psilocybin Therapy Shows Promise for Severe PTSD in Veterans
- Psilocybin Trial Shows Sustained Improvements in Anorexia
- Psilocybin: Emotional and Cognitive Modulation Under Scientific Lens
- Psychedelic Integration: From the Trip to Lasting Change
- Psychedelic Medicine: A Practical Guide for Patients and Clinicians
- Psychedelic Microdosing: What Placebo-Controlled Trials Reveal
- Psychedelic Psychotherapy Examined: What Does Evidence Say?
- Psychedelic Visions and the Brain: Beyond Huxley
- Psychonauts on the Net
- Puerto Rico launches pilot program to research psychedelics
R
- Real Efficacy of Cannabis Oil Rubs: Science, Myths, and Harm Reduction
- Real-world study finds no liver damage from ketamine or esketamine
- Recreational vs. Clinical Ketamine: Uses and Harm Reduction
- Regulating Drugs (Part 5): Demand, Home Cultivation, and Prevention
- Regulating Drugs: Sales, Legal Age, and Pricing Models
- Relaxation and Cannabis: Mechanisms, Techniques, and Cautions
- Rigorous Trial Questions Ketamine Efficacy for Depression
- Rimonabant: The Drug That Blocked the Mind Before the Appetite
S
- Sacred Plants and Ethnomedicine: From Kava to Iboga
- Salvia divinorum Effects: Why They Are So Intense and Brief
- Salvia divinorum: Legal Status in Spain and Worldwide
- Salvia divinorum: Real Risks and Harm Reduction Essentials
- Salvia divinorum: The Visionary Plant of the Mazatecs
- Salvinorin A in Humans: 12 Trials and 174 Participants Reviewed
- Salvinorin A: The Most Potent Natural Psychedelic and the Kappa Receptor
- San Pedro (Trichocereus): Mescaline from Andean Cacti
- Scotland to Open First Drug Checking Service in Glasgow
- Second Phase 3 Trial Shows Positive LSD Results for Anxiety
- Setting Modulates Psilocybin’s Effect on Synaptic Density
- Shamanic Journeying Without Hallucinogens
- Shulgin (I): The Chemical Vocation of a Psychonaut
- Shulgin and MDMA: From Merck’s Archives to the Personal Lab
- Shulgin and MDMA: From the Merck Archives to the Home Lab
- Single Dose of DMT Reduces Treatment-Resistant Depression
- Single Dose of Pharmaceutical LSD Reduces Major Depression in Phase 3
- Snow Sports and MDMA: A Rigorous Look at Vital Risks
- Spanish Fly: Between Historical Legend and Chemical Reality
- Spiderwebs and Hallucinations: Urban Myth vs. Scientific Reality
- Stiff-Person Syndrome: Neurophysiology and Therapeutic Cannabis
- Study Debunks Ancestral Myth of 5-MeO-DMT Toad
- Sustainable Drugophilia: Regulating Drugs Instead of Prohibition
- Sustainable Hedonism (Part 7): Safer Drugs and Destigmatizing Users
- Sustainable Hedonism: From Prohibition to Pleasure Management
- Sydney Injection Site: 16 of 77 Drug Samples Contained Surprises
- Synthetic Ayahuasca Analog Accelerates Brain Activity
- Synthetic Cannabinoids: A Safe Substitute for Medical Cannabis?
- Synthetic Cannabinoids: Between Technical Legality and Vital Risk
- Synthetic Cannabinoids: The Shadow of Modern Recreation
- Synthetic Cannabinoids: The Spice Phenomenon and Hidden Risks
T
- Tampodka: Anatomy of a Summer Drug Hoax
- Testosterone: Between Biology, Power, and the Construction of Gender
- Texas Launches Its Own Ibogaine Clinical Trials Without Big Pharma
- The 1965 Paper That Turned a Canary Broom Into a “Minor Psychedelic”
- The Amsterdam Hash Marihuana & Hemp Museum: Forgotten History
- The Art of Cannavaping: Science, Risks, and Therapeutic Future
- The Banana Peel Myth: Between Pop Culture and Science
- The Bwiti Ritual: Traditional Iboga Use in Gabon
- The Central Role of Entheogens in Cultural Dynamics
- The Crystal Deception: Meth Sold as Ecstasy in Spain
- The Evolution of Drug Advertising: From Prohibition to Responsibility
- The Foster’s Beer LSD Synthesis Legend: Myth vs. Chemical Reality
- The Haitian Zombie Myth: Science, Faith, and Clairvius Narcisse
- The Historical Eclipse of Entheogens
- The History of Ketamine: From the Operating Room to Psychiatry
- The HIV Syringe in the Movie Theater Seat Hoax
- The Invisible Ally of the Monteverde: The Canary Broom’s Secret Life
- The Largest Global Survey Reveals How Microdosing Is Practiced Today
- The Medicinal Side of Power Plants
- The Most Well-Known Chemical Psychoactives
- The Myth of the Miracle Oil: Why Rick Simpson’s Case Isn’t Science
- The Opioid Crisis: Heroin, Morphine, and the Pharmaceutical Industry
- The Renaissance of LSD in Clinical Research for Palliative Care
- The Rick Simpson Myth: Between Desperate Hope and Science
- The Risk of a Psychedelic Theocracy: Mysticism vs. Rigorous Science
- The Role of Physicians in Medical Cannabis: Reality and Myths
- The Science of Aspirin and Coke: Debunking a Persistent Myth
- The Shadow of the Stimulant: Methamphetamine and Europe’s New Challenges
- The Sixth Decade of Cannabis: A Century of Silence and Science
- The Therapeutic User: Rigor, Responsibility, and Science in Clubs
- The Truth About Amphetamine Storage: Myths vs. Chemical Reality
- The Truth About Rat Poison in Drugs: History, Science, and Myths
- The Truth About Smoking Toothpaste: Myths, Fluoride, and Science
- Therapeutic Cannabis: History, Law, and Myth
- Therapeutic Cannabis: Scientific Obstacles and the Shadow of Prohibition
- Three Spanish Hospitals Validate Esketamine for Resistant Depression
- Tolerance and Loss of Effects: Pharmacological Keys to MDMA
- Toxicomania: The Substance or the Temperament?
- Traditional Mazatec Use: María Sabina and the Leaves of the Shepherdess
- Turkestan Mint: The Forgotten Sedative of Central Asia
- Turkestan Mint: The Forgotten Sedative of Central Asia
- Two Psilocybin Doses for OCD: Johns Hopkins Trial Results
U
- U.S. Funds MDMA Therapy for Active-Duty Soldiers with PTSD
- UK Clinic Treats 60 Minors for Ketamine-Induced Bladder Damage
- UK public healthcare tests psilocybin against true placebo
- UK to control ethylbromazolam after finding it in fake pills
- Understanding Iboga: The African Shrub and Ibogaine Alkaloid
- Urinary Incontinence and Cannabinoids: Clinical Evidence and Risk Reduction
- Urine Drug Tests: Scientific Reality and Myths About Cannabis
- US Congress Releases Roadmap for Psychedelic Therapy
- US Court Keeps Medical Cannabis in Schedule III
- US Department of Veterans Affairs Launches PIVOT Psilocybin Trial
- US Issues Alert on Three Fentanyl Analogues Linked to 12,500 Deaths
- US Launches Federal Funding for Ibogaine Clinical Trials
- US Proposes Placing Five Psychedelic Tryptamines in Schedule I
- US Receives 59 Proposals on Implementing Psychedelic Therapy
- US Survey Links Psychedelic Decriminalization to Increased Safety
- US VA Launches MDMA Trial for Veterans with PTSD and Alcoholism
W
- Wales Detects New Synthetic Opioids Sold as Heroin
- We Are Standard: Danceable Pop, London, and the Cannabis Question
- Weed Fertilized with LSD: Anatomy of an Urban Legend
- Welcome to Psiconáutica
- Welcome Traveler to Your First Gateway
- Western surge in huachuma reopens ethical debate with the Andes
- What Canary Broom Can Still Teach Science
- What Is Ketamine: Pharmacology, Effects, and Medical Uses
- What Is Salvia Divinorum: The Mazatec Visionary Plant
- When Crack Replaces Heroin in Madrid
- Why Marijuana Is Illegal: The History of Prohibition
- Wild Psychoactive Plants of the Iberian Peninsula (Part 1)
